Incidence of Invasive Breast Cancer in Postmenopausal Women After Discontinuation of Long-Term Raloxifene Administration

Geller, 2005, Chemoprevention of breast cancer in postmenopausal women, Breast Dis, 24, 79, 10.3233/BD-2006-24107 American Cancer Society, 2007 1975 Veronesi, 2005, Breast cancer, Lancet, 365, 1727, 10.1016/S0140-6736(05)66546-4 2003 Fisher, 1996, Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors, J Natl Cancer Inst, 88, 1529, 10.1093/jnci/88.21.1529 2007 Vogel, 2006, Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial [published errata in: JAMA 2006; 296:2926 and JAMA 2007; 298:973], JAMA, 295, 2727, 10.1001/jama.295.23.joc60074 Cuzick, 2003, Overview of the main outcomes in breastcancer prevention trials, Lancet, 361, 296, 10.1016/S0140-6736(03)12342-2 Fisher, 1998, Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, J Natl Cancer Inst, 90, 1371, 10.1093/jnci/90.18.1371 Cuzick, 2002, First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial, Lancet, 360, 817, 10.1016/S0140-6736(02)09962-2 Powles, 1998, Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial, Lancet, 352, 98, 10.1016/S0140-6736(98)05071-5 Veronesi, 1998, Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study, Lancet, 352, 93, 10.1016/S0140-6736(98)85011-3 Cuzick, 2007, Long-term results of tamoxifen prophylaxis for breast cancer–96-month follow-up of the randomized IBIS-I trial, J Natl Cancer Inst, 99, 272, 10.1093/jnci/djk049 Powles, 2007, Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial, J Natl Cancer Inst, 99, 283, 10.1093/jnci/djk050 Veronesi, 2007, Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy, J Natl Cancer Inst, 99, 727, 10.1093/jnci/djk154 Veronesi, 2007, Tamoxifen: an enduring star, J Natl Cancer Inst, 99, 258, 10.1093/jnci/djk072 Cauley, 2001, Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation [published erratum in: Breast Cancer Res Treat 2001; 67:191], Breast Cancer Res Treat, 65, 125, 10.1023/A:1006478317173 Martino, 2004, Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene, J Natl Cancer Inst, 96, 1751, 10.1093/jnci/djh319 Barrett-Connor, 2006, Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women, New Engl J Med, 355, 125, 10.1056/NEJMoa062462 Ettinger, 1999, JAMA, 282, 637, 10.1001/jama.282.7.637 Delmas, 2002, Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial, J Clin Endocrinol Metab, 87, 3609, 10.1210/jc.87.8.3609 Fisher, 2001, Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial, J Natl Cancer Inst, 93, 684, 10.1093/jnci/93.9.684 Rosenbaum, 1983, The central role of the propensity score in observational studies for causal effects, Biometrika, 70, 41, 10.1093/biomet/70.1.41 Qu, 2009, Propensity score estimation with missing values using multiple imputation missingness pattern (MIMP) approach, Stat Med, 10.1002/sim.3549 Costantino, 1999, Validation studies for models projecting the risk of invasive and total breast cancer incidence, J Natl Cancer Inst, 91, 1541, 10.1093/jnci/91.18.1541 Siris, 2005, Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study, J Bone Miner Res, 20, 1514, 10.1359/JBMR.050509 Abukhdeir, 2008, Tamoxifen-stimulated growth of breast cancer due to p21 loss, Proc Natl Acad Sci U S A, 105, 288, 10.1073/pnas.0710887105 Osipo, 2005, Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy, J Steroid Biochem Mol Biol, 93, 249, 10.1016/j.jsbmb.2004.12.005 Canney, 1987, Clinical significance of tamoxifen withdrawal response, Lancet, 1, 36, 10.1016/S0140-6736(87)90717-3 Howell, 1992, Response after withdrawal of tamoxifen and progestogens in advanced breast cancer, Ann Oncol, 3, 611, 10.1093/oxfordjournals.annonc.a058286 Dosik, 2004, Raloxifene rebound regression, Cancer Invest, 22, 718, 10.1081/CNV-200032978 Jordan, 2005, The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy, Breast, 14, 624, 10.1016/j.breast.2005.08.022 Robertson, 2005, Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant, Breast Cancer Res Treat, 92, 169, 10.1007/s10549-004-4776-0 Fisher, 2005, Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study, J Natl Cancer Inst, 97, 1652, 10.1093/jnci/dji372 Costantino, 2001, Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials: an alternative view, Clin Breast Cancer, 2, 41, 10.3816/CBC.2001.n.009 Veronesi, 2003, Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women, J Natl Cancer Inst, 95, 160, 10.1093/jnci/95.2.160 Vogel, 2003, Preventing hormone-dependent breast cancer in high-risk women, J Natl Cancer Inst, 95, 91, 10.1093/jnci/95.2.91